¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"time factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® rheumatoid factor ÇÑ±Û ·ù¸¶Æ¼½º ÀÎÀÚ
¼³¸í   
  IgGÀÇ FcºÎÀ§¿¡ Àִ Ç׿ø°áÁ¤ÀÎÀÚ¿¡ ´ëÇÑ Ç×ü·Î¼­ ÀüÇüÀûÀΠ¶Ç´Â È®½ÇÇÑ ·ù¸¶Æ¼½º°üÀý¿°(rheumatoid arthritis) È¯ÀÚÀÇ 80%¿¡¼­ ¹ß°ßµÈ´Ù. ·ù¸¶Æ¼½º ÀÎÀڴ IgM, IgG, IgAÁß Çϳª°¡ µÉ ¼ö ÀÖÀ¸³ª ÁַΠIgMÀÌ´Ù. ¼Ò¾Æ·ù¸¶Æ¼½º°üÀý¿°(juvenile rheumatoid arthritis: ¼Ò¾Æ±â¿¡ ¹ß»ýÇϴ ·ù¸¶Æ¼½º°üÀý¿°)À» ºñ·ÔÇÑ, ´Ù¸¥ °áÇÕÁ¶Á÷º´À̳ª °¨¿°º´¿¡µµ ³ªÅ¸³¯ ¼ö ÀÖ´Ù
¿µ¹® growth factor ÇÑ±Û ¼ºÀåÀÎÀÚ
¼³¸í   
  ¼¼Æ÷ÀÇ ºÐÈ­ ¹× ¼ºÀå¿¡ °ü¿©Çϴ ´Ü¹éÁú. ¼ºÀåÀÎÀڴ Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ Å¾ÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù.
¿µ¹® risk factor ÇÑ±Û À§ÇèÀÎÀÚ
¼³¸í   
  ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼­ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î Ã¤ÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£­3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£­3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ À־ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£­3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼­ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» Çϸ鼭 ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£­3/SvÀÌ´Ù.
¿µ¹® coagulation time ÇÑ±Û ÀÀ°í½Ã°£
¼³¸í   
  Ç÷¾×ÀÀ°í¶õ ÁöÇ÷ÀÇ ÇÑ °úÁ¤À¸·Î ¼¶À¯¼Ò¶õ ¹°ÁúÀ» ¸¸µé¾î ³»´Â °úÁ¤ÀÌ´Ù. ÀÌ ¼¶À¯¼Ò¶õ ¹°ÁúÀº ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¿¡ ÀÛ¿ëÇÏ¿© ¿©·¯ °¡Áö ¼¼Æ÷µéÀ» ¾ô¾î ¹­´Â ¿ªÇÒÀ» ÇÏ¿© °á±¹ ¼Õ»óµÈ Ç÷°ü¿¡¼­ Ç÷¾×ÀÇ ¼Ò½ÇÀ» ¸·´Â´Ù. Ç÷¾×ÀÀ°í´Â ´ÙÀ½°ú °°Àº 3´Ü°è·Î ÀÌ·ç¾îÁø´Ù.
  
  Ã¹¹øÂ° ´Ü°è´Â Ç÷°ü¼Õ»ó¿¡ ÀÇÇØ¼­ prothrombin activator¶ó´Â °ÍÀÌ ¸¸µé¾îÁö´Â ´Ü°èÀÌ´Ù. µÎ¹øÂ° ´Ü°è´Â ÀÌ prothrombin activator¶ó´Â ¹°Áú¿¡ ÀÇÇØ¼­ Ç÷¾×¼Ó¿¡ Àִ ÇÁ·ÎÆ®·ÒºóÀ̶ó´Â ¹°ÁúÀÌ Æ®·ÒºóÀ̶ó´Â ¹°Áú·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ¼¼¹øÂ° ´Ü°è´Â Æ®·ÒºóÀ̶ó´Â ¹°Áú¿¡ ÀÇÇØ¼­ ¼¶À¯¼Ò¿øÀ̶ó´Â ¹°ÁúÀÌ ¼¶À¯¼ÒÀ¸·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù.
  
  ÀÀ°íÀÛ¿ëÀº Å©°Ô 2°¡Áö·Î ³ª´µ´Âµ¥, ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀÚ°¡ ±×°ÍÀÌ´Ù. ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀڴ °¢±â º°°³·Î ÀÛ¿ëÇÏÁö¸¸, °á±¹Àº ¸¶Áö¸· °úÁ¤¿¡¼­ Çϳª·Î ¸¸³ª¼­ ¼¶À¯¼Ò¿øÀ» ¼¶À¯¼Ò(ÀÀ°íÀÛ¿ëÀÇ ¸¶Áö¸· ´Ü°è¿¡ »ý¼ºµÇ¸ç ´Ü´ÜÇϰí Ç®¸®Áö ¾Ê´Â ¸ÅµìÀ» Çü¼ºÇÏ¿© ÁöÇ÷ÀÛ¿ëÀ» ¿Ï¼ºÇÑ´Ù)À¸·Î ¸¸µé¾î ÀÀ°íÀÛ¿ëÀ» ³ªÅ¸³½´Ù.
¿µ¹® bleeding time ÇÑ±Û ÃâÇ÷½Ã°£
¼³¸í   
  ¸ö¿¡ »óó°¡ ³ª¼­ ÃâÇ÷ÀÌ ÀÖ¾úÀ» °æ¿ì¿¡ Çǰ¡ ¸Ü´Âµ¥ ±îÁö °É¸®´Â ½Ã°£À» ÃâÇ÷½Ã°£À̶ó°í ÇÑ´Ù. »ç¶÷ÀÇ ¸ö¿¡ »óó°¡ ³ª¼­ ÃâÇ÷ÀÌ ÀÖÀ» °æ¿ì¿¡ À̰ÍÀ» ¸·°í ÇǸ¦ ´õÀ̻󠳪Áö ¾Ê°Ô Çϴ °ÍÀ» ÁöÇ÷À̶ó°í ÇÑ´Ù. ÁöÇ÷ÀÇ °úÁ¤¿¡´Â Å©°Ô µÎ °¡Áö ´Ü°è°¡ ÀÖ´Ù. Ã¹¹øÂ° ´Ü°è´Â Ç÷¼ÒÆÇµéÀÌ »óó°¡ ³ª¼­ ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¸¦ ¸·´Â °ÍÀÌ´Ù. ÀÌ·¸°Ô Çϸ頿켱 Ç÷°üÀÇ ¼Õ»óºÎÀ§·ÎºÎÅÍ Çǰ¡ ³ª¿À´Â °ÍÀ» ¸·À» ¼ö°¡ ÀÖ´Ù. ´ÙÀ½ÀÇ ´Ü°è´Â »ó󸦠¸·°í Àִ Ç÷¼ÒÆÇÀ§¿¡ ¿©·¯ °¡Áö ¹°ÁúµéÀÌ ÀÛ¿ëÇØ¼­ ´õ¿í ´Ü´ÜÇϰԠÇÏ¿© »óó°¡ ³­ Ç÷°ü¿¡¼­ Çǰ¡ »õ´Â °ÍÀ» ¿µ±¸È÷ ¸·´Â °ÍÀÌ´Ù. ½±°Ô ¸»Çϸé Ç÷¼ÒÆÇÀº º®µ¹¿¡ ÇØ´çÇϴ °ÍÀÌ°í µÎ¹øÂ° °úÁ¤¿¡ Âü¿©Çϴ ¹°ÁúµéÀº ½Ã¸àÆ®¿¡ ÇØ´çÇϴ °ÍÀÌ´Ù. ÀÌ µÎ °úÁ¤ÀÌ ¿ÏÀüÇÒ °æ¿ì¿¡ ÁöÇ÷ÀÌ ¼øÁ¶·Ó°Ô ÀϾ´Ù.
  
  ÃâÇ÷½Ã°£Àº À§¿¡¼­ ¼³¸íÇÑ ÁöÇ÷ÀÇ µÎ°¡Áö °úÁ¤ Áß¿¡¼­ Ã¹¹øÂ° °úÁ¤¿¡ ÀÇÇØ¼­¸¸ ¿µÇâÀ» ¹Þ´Â´Ù. Áï ¼Õ»óµÈ Ç÷°üÀ» ¸·¾ÆÁִ º®µ¹¿¡ ÇØ´çÇϴ Ç÷¼ÒÆÇÀÇ ±â´É¸¸ Á¤»óÀÏ °æ¿ì¿¡ ÃâÇ÷½Ã°£Àº Á¤»óÀ¸·Î ³ª¿Â´Ù. ¸¸¾à Ç÷¼ÒÆÇÀÇ ±â´É¿¡ ÀÌ»óÀÌ Àִ °æ¿ì¿¡´Â ÀÚ¿¬È÷ ÃâÇ÷½Ã°£ÀÌ ±æ¾îÁø´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£
  • atrioventricular conduction time
    ¹æ½ÇÀüµµ½Ã°£
  • acquisition time
    ȹµæ½Ã°£
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • bleeding time
    ÃâÇ÷½Ã°£
  • bleeding time test
    ÃâÇ÷½Ã°£°Ë»ç
  • breath holding time
    ¼ûÂü´Â½Ã°£, È£ÈíÁßÁö½Ã°£
  • circulation time
    ¼øÈ¯½Ã°£
  • clot retraction time
    ÇǶ±µÞ´ç±è½Ã°£, Ç÷º´¼öÃà½Ã°£
  • clotting time
    ÀÀ°í½Ã°£
  • coagulation time
    ÀÀ°í½Ã°£
  • colonic transit time
    ´ëÀåÅë°ú½Ã°£
  • concentration-time curve
    Ç÷Áß³óµµ°î¼±
  • conduction time
    Àüµµ½Ã°£
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • factor
    ÀÎÀÚ, ¿äÀÎ, °è¼ö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • antiplatelet factor
    Ç×Ç÷¼ÒÆÇÀÎÀÚ
  • coagulation V factor
    Á¦5Ç÷¾×ÀÀ°íÀÎÀÚ
  • exclusion of confounding factor
    ±³¶õº¯¼ö¹èÁ¦
  • growth factor
    ¼ºÀåÀÎÀÚ
  • intrinsic factor
    ³»ÀÎÀÎÀÚ, ³»ÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • precipitation factor
    ÃËÁø¿äÀÎ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • time-dose factor
    ½Ã°£¼±·®ÀÎÀÚ
  • acquisition time
    ȹµæ½Ã°£
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£
  • atrioventricular conduction time
    ¹æ½ÇÀüµµ½Ã°£
  • real time acquisition
    ½Ç½Ã°£È¹µæ
  • bleeding time
    ÃâÇ÷½Ã°£
  • bleeding time test
    ÃâÇ÷½Ã°£°Ë»ç
  • breath holding time
    ¼ûÂü´Â½Ã°£
  • lead-time bias
    Á¶±â¹ß°ß±â°£¹ÙÀ̾
  • clot retraction time
    Ç÷º´ÅðÃà½Ã°£, Çǵ¢À̵ڴç±è½Ã°£
  • clotting time
    (¢¡coagulation time) ÀÀ°í½Ã°£
  • coagulation time
    ÀÀ°í½Ã°£
  • concentration-time curve
    Ç÷Áß³óµµ°î¼±
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • F factor (fertility factor)
    FÀÎÀÚ, ¼öÅÂÀÎÀÚ
  • AUC : area under the concentration-time curve
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
  • BUT->breakup time of tear film
    ´«¹°¸·ÆÄ±«½Ã°£, ´©¾×¸·ÆÄ±«½Ã°£
  • Conduction time
    Àüµµ½Ã°£
  • MTT=£¾mean tidal time
    Æò±Õ¼øÈ¯½Ã°£.
  • Russells viper venom time
    ·¯¼¿¹ÙÀÌÆÛº£³ð½Ã°£
  • T.G.C (time gain compensation)
    ½Ã°£ (ãÁÊà) °ÔÀÎ º¸»ó (ÜÍßÁ), °Å¸®(±íÀÌ) °ÔÀÎ º¸»ó
  • T.G.C (time gain compensation)
    ½Ã°£ °ÔÀÎ º¸»ó
  • T1 relaxation time
    T1 ÀÌ¿Ï ½Ã°£
  • T2 (spin spin) relaxation time
    T2(½ºÇɽºÇÉ) À̿Ͻð£
  • T2 relaxation time
    T2 ÀÌ¿Ï ½Ã°£
  • TM scan(Time motion)
    ½Ã°£ ¿îµ¿ ¹æ½Ä
  • TM-scan(Time motion)
    ½Ã°£ ¿îµ¿ ¹æ½Ä (ãÁÊà ê¡ÔÑ Û°ãÒ)
  • TOF (time of flight)
    È帧 ½Ã°£ TOF(Ƽ¿À¿¡ÇÁ), À¯Ã¼ ¼Óµµ °­?
  • acquisition time
    ȹµæ ½Ã°£
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • time factor
    ½Ã°£ÀÎÀÚ(ãÁÊàì×í­).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • time, dose and fractionation factor, TDF factor
    ½Ã°£¼±·®ºÐÇÒÀÎÀÚ
  • time-dose factor
    ½Ã°£¼±·®ÀÎÀÚ
  • col factor(»ýÈ­) cÀÌ ÀÎÀÚ colicin factor
    Äݸ®½ÅÀÎÀÚ.
  • lupus erythematosus factor = LE factor
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­)
  • acquisition time
    ȹµæ ½Ã°£
  • activated clotting time
    Ȱ¼ºÈ­ÀÀ°í½Ã°£
  • activated coagulation time(ACT)
    Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
  • activated coagulation time=ACT
    Ȱ¼ºÈ­ ÀÀ°í½Ã°£
  • activated partial prothrombin time
    Ȱ¼º ºÎºÐÇÁ·ÎÆ®·Òºó½Ã°£
  • activated partial thromboplastin time
    Ȱ¼º ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • activated partial thromboplastin time =aPTT
    Ȱ¼ºÈ­ ºÎºÐ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ½Ã°£
  • appearance time
    ÃâÇö½Ã°£(õóúÞãÁÊà) ¼øÈ¯(âàü») .
  • area under the concentration-time curve : AUC
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
  • arm to tongue time test
    ÆÈÇô¼øÈ¯½Ã°£½ÃÇè
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£, ¿Ï-¸Á¸·¼øÈ¯½Ã°£
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Duffy factor
    ´õÇÇÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • time factor effect
    ½Ã°£ÀÎÀÚ È¿°ú (ãÁÊàì×í­üùÍý)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • assimilation time
    µ¿È­ÀÛ¿ë ½Ã°£ (ÔÒûùíÂéÄãÁÊà)
  • clotting time
    ÀÀ°í½Ã°£(ëêͳãÁÊà)
  • coincidence time
    µ¿½Ã½Ã°£(ÔÒãÁãÁÊà)
  • double beam in time spectrophotometer
    ½Ö±¤¼Ó ½Ã°£ ºÐ±¤±¤µµ°è(äªÎÃãÁÊàáÜÝÂÎÃÎÃÓøÍª)
  • elution time
    ¿ë¸® ½Ã°£ (éÁ×îãÁÊà)
  • fixed time assay
    ÀÏÁ¤½Ã°£(ìéïÒãÁÊà) ¾Æ½êÀÌ
  • generation time
    ¼¼´ë ½Ã°£(á¦ÓÛãÁÊà)
  • generation-time hypothesis
    ¼¼´ë ½Ã°£ ¼³(á¦ÓÛãÁÊààã)
  • half-reaction time
    ¹Ý¹ÝÀÀ ½Ã°£(ÚâÚãëëãÁÊà)
  • half-time
    ¹Ý ½Ã°£(ÚâãÁÊà)
  • high-temperature-short-time method
    °í¿Â ´Ü½Ã°£¹ý(ÍÔè®Ó­ãÁÊàÛö)
  • mean generation time
    Æò±Õ¼¼´ë±â°£(øÁгá¦ÓáÑ¢Êà)
  • recovery time
    ȸ¼ö ½Ã°£(üÞâ¥ãÁÊà)
  • relaxation time
    ÀÌ¿Ï ½Ã°£(ì¬èÐãÁÊà)
  • residence time
    µ¿°Å ½Ã°£(ÔÒËÜãÁÊà)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • attenuation factor
    °¨¾à¿ä¼Ò, °¨¼è¿äÀÎ
  • conversion factor
    º¯È¯ÀÎÀÚ
  • factor
    ÀÎÀÚ
  • predisposing factor
    ¼ÒÀÎ, Áúº´¼ÒÁú
  • Q factor
    Å¥ÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½º¾çÀÎÀÚ
  • risk factor
    À§Çè¿äÀÎ
  • turbo factor
    Åͺ¸ÀÎÀÚ
  • acquisition time
    ȹµæ½Ã°£
  • arm to lung time test
    ÆÈÆó¼øÈ¯½Ã°£½ÃÇè
  • correlation time
    »ó°ü½Ã°£
  • data acquisition time
    ÀÚ·áȹµæ½Ã°£
  • delay time
    Áö¿¬½Ã°£
  • diffusion time
    È®»ê½Ã°£
  • doubling time
    ¹è°¡½Ã°£
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CF calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ...
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
PTT partial thromboplastin time; particle transport time; posterior tibial tendon (transfer); prothrombi...
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
PF pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
TE time , expiratory time
D factor Differentiation-stimulating factor
TRAF Factor Receptor-associated factor
FVIII-vWF Factor VIII-von Willebrand Factor
Factor Xa Factor X
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • IGF-I : insulin like growth factor-IÀÇ ¾àÀÚ. ¼ºÀåÆÇÀÎ epiphyseal plate¿¡ ¿¬°ñ »ý¼ºÀ» Áõ°¡½ÃÄÑ »ÀÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

    IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡

    Àν¶¸°¾ç ¼ºÀå ÀÎÀÚ °áÇÕ ´Ü¹éÁú
    insulinelike growth factor binding
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • acquisition time
    ȹµæ ½Ã°£
  • activated coagulation time
    Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
  • area under the concentration-time curve
    Ç÷Áß ³óµµ °î¼±ÇÏ ¸éÀû, Ç÷Áß ¾à¹° ³óµµ °î¼±ÇÏ ¸éÀû
  • arm to lung time test
    ÆÈ Æó ¼øÈ¯ ½Ã°£ ½ÃÇè
  • arm-to-retina circulation time
    ÆÈ ¸Á¸· ¼øÈ¯ ½Ã°£
  • bleeding time test
    ÃâÇ÷ ½Ã°£ ½ÃÇè
  • chair time
    Áø·á ½Ã°£, Ä¡·á ½Ã°£
    ȯÀÚ°¡ Áø´Ü ¹× Ä¡·á ¹Þ±â À§ÇÑ ½Ã°£.
  • change over time
    ½Ã°£¿¡ µû¸¥ º¯È­
  • coagulation time
    ÀÀ°í ½Ã°£
  • contact time
    Á¢ÃË ½Ã°£
  • correlation time
    »ó°ü ½Ã°£
  • doubling time
    ¹è°¡ ½Ã°£
  • echo time
    ¿¡ÄÚ ½Ã°£
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
time factors Elements of limited time intervals, contributing to particular results or situations.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
activated clotting time The most common test used for coagulation time in cardiovascular surgery.
(05 Mar 2000)
activated partial thromboplastin time The time needed for plasma to form a fibrin clot following the addition of calcium and a phospholipid reagent; used to evaluate the intrinsic clotting system.
(05 Mar 2000)
A-H conduction time Forward conduction of the cardiac impulse from atria to ventricles via the A-V node or any bypass tract, represented in the electrocardiogram by the P-R interval. P-H conduction time is from the onset of the P wave to the first high frequency component of the His bundle electrogram (normally 119 ± 38 msec); A-H conduction time is from the onset of the first high frequency component of the atrial electrogram to the first high frequency component of the His bundle electrogram (normally 92 ± 38 msec); P-A conduction time is from the onset of the P wave to the onset of the atrial electrogram (normally 27 ± 18 msec).
(05 Mar 2000)
association time Time elasping between a stimulus and the verbalised response to it.
(05 Mar 2000)
biologic time The concept that our appreciation of time varies with age and is governed by the neural organization of the individual; it obeys a logarithmic rather than an arithmetic law.
(05 Mar 2000)
bleeding time <haematology> A test which measures the time it takes for small blood vessels to close off and bleeding to stop. Abnormal results can be seen in those with congenital or acquired platelet function disorders or thrombocytopenia.
(27 Sep 1997)
blood circulation time Determination of the shortest time interval between the injection of a substance in the vein and its arrival at some distant site in sufficient concentration to produce a recognizable end result. It represents approximately the inverse of the average velocity of blood flow between two points.
(12 Dec 1998)
P-A conduction time See: atrioventricular conduction.
(05 Mar 2000)
generation time <cell biology> Time taken for a cell population to double in numbers and thus equivalent to the average length of the cell cycle.
(18 Nov 1997)
reaction time The time from the onset of a stimulus until the organism responds.
(12 Dec 1998)
real-time ultrasonography Rapid serial ultrasound images produced using a phased array or scanning transducer; produces a video display of organ motion, such as heart valve or foetal motion.
(05 Mar 2000)
recognition time The interval between the application of a stimulus and the recognition of its nature.
(05 Mar 2000)
partial thromboplastin time Test of the intrinsic (factors viii, ix, xi, and xii) and common (fibrinogen, prothrombin, factors v and x) pathways of coagulation in which a mixture of plasma and phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides) is recalcified and the time required for the appearance of fibrin strands measured. Activation may be provided by contact with the glass tube or exposure to activators (e.g., ellagic acid, particulate silicates such as diatomaceous earth or kaolin) before addition of the calcium chloride. It is used as a screening test and to monitor heparin therapy.
(12 Dec 1998)
relaxation time Time taken for a system to return to the resting or ground state or a new equilibrium state following perturbation. Often used in context of receptor systems that have a refractory period after responding and then relax to a competent state. Can be used more precisely to mean the time for a system to change from its original equilibrium value to 1/e of this original value.
(18 Nov 1997)
median time to elimination <pharmacology> The time it takes one half of a drug to be eliminated from the body.
(09 Oct 1997)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Time Factors - »õâ Elements of limited time intervals, contributing to particular results or situations.
    Synonyms : Factor, Time, Factors, Time, Time Factor
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • factor
    ¿ä¼Ò,¿äÀÎ
  • F factor
    FÀÎÀÚ;¿°¼ºÀÎÀÚ
  • R factor
    R ÀÎÀÚ(¼¼±ÕÀÇ ¾àÁ¦ ³»¼º ÀÎÀÚ)
  • Rh factor
    ¸®¼­½º ÀÎÀÚ(ÀûÇ÷±¸ ¼Ó¿¡ ÀÖ´Â ÀÀÇ÷¼Ò)
  • Rhesus factor(antigen)
    =RH FACTOR
  • coal-factor
    ¼®Åº Áß°³ »óÀÎ(µµ¸Å »óÀÎ)
  • common factor
    =COMMON DIVISOR
  • conversion factor
    (¹®ÀÇ.ÀÚ·áû±¸¿¡¼­ ½ÇÁ¦ »óǰ±¸¸ÅÀÎÀ¸·ÎÀÇ)ÀüȯÀ²
  • factor
    ¿ä¼Ò;¿äÀÎ;¿øÀÎ;Àμö;ÀÎÀÚ;°è¼ö;À²;´ë¸®»ó;µµ¸Å»ó;Á߸ÅÀÎ
  • factor analysis
    ÀÎÀÚ ºÐ¼®
  • factor cost
    ¿äÀÎ(¿ä¼­)ºñ¿ë
  • intrinsic factor
    (»ýÈ­)³»À缺ÀÎÀÚ
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
  • noise factor(figure)
    (ÁõÆø±â¿¡¼­ÀÇ)ÀâÀ½Áö¼ö
  • pp factor
    Ç× Æç¶ó±×¶ó ÀÎÀÚ(Æç¶ó±×¶ó ¿¹¹æ¿¡ ¾²´Â ´ÏÄÚÆ¾»ê,´ÏÄÚÆ¾»ê¸¶À̵å)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á